TRPC5 and post-traumatic stress disorder: BI 1358894, a small-molecule inhibitor of TRPC5, is currently being developed for clinical use in the treatment of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD)36, 37, 38.